The emerging pharmacology and function of GPR35 in the nervous system

Neuropharmacology

Volumn 113, Issue , 2017, Pages 661-671

  Mackenzie, Amanda E ^a   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CNS; GPR35; Kynurenic acid; Pain; Synaptic transmission; Zaprinast

Indexed keywords

CROMOGLYCATE DISODIUM; EMBONIC ACID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 35; GENOMIC DNA; KYNURENIC ACID; MORPHINE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; SILDENAFIL; UNCLASSIFIED DRUG; ZAPRINAST;

ALBRIGHT SYNDROME; ANALGESIC ACTIVITY; AUTISM; BILE DUCT DISEASE; CENTRAL NERVOUS SYSTEM; CHROMOSOME; CHROMOSOME 2Q; CHROMOSOME DELETION; COLITIS; COPY NUMBER VARIATION; DRUG DOSE COMPARISON; DRUG TARGETING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INFLAMMATORY PAIN; MAST CELL; MOLECULAR PATHOLOGY; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NOCICEPTION; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPTIC TRANSMISSION; VISCERAL PAIN; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84939186174     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.07.035     Document Type: Review

References (119)

1. Alkondon, M., Pereira, E.F., Albuquerque, E.X., Endogenous activation of nAChRs and NMDA receptors contributes to the excitability of CA1 stratum radiatum interneurons in rat hippocampal slices: effects of kynurenic acid. Biochem. Pharmacol. 82 (2011), 842–851, 10.1016/j.bcp.2011.06.004.
2. Alkondon, M., Pereira, E.F., Todd, S.W., Randall, W.R., Lane, M.V., Albuquerque, E.X., Functional G-protein-coupled receptor 35 is expressed by neurons in the CA1 field of the hippocampus. Biochem. Pharmacol. 93 (2015), 506–518, 10.1016/j.bcp.2014.12.009.
3. Alt, A., Weiss, B., Ogden, A.M., Knauss, J.L., Oler, J., Ho, K., Large, T.H., Bleakman, D., Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology 46 (2004), 793–806, 10.1016/j.neuropharm.2003.11.026.
4. Banerjee, J., Alkondon, M., Albuquerque, E.X., Kynurenic acid inhibits glutamatergic transmission to CA1 pyramidal neurons via α7 nAChR-dependent and -independent mechanisms. Biochem. Pharmacol. 84 (2012), 1078–1087, 10.1016/j.bcp.2012.07.030.
5. Barth, M.C., Ahluwalia, N., Anderson, T.J., Hardy, G.J., Sinha, S., Alvarez-Cardona, J.A., Pruitt, I.E., Rhee, E.P., Colvin, R.A., Gerszten, R.E., Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J. Biol. Chem. 284 (2009), 19189–19195, 10.1074/jbc.M109.024042.
6. Beavo, J.A., Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75 (1995), 725–748.
7. Berlinguer-Palmini, R., Masi, A., Narducci, R., Cavone, L., Maratea, D., Cozzi, A., Sili, M., Moroni, F., Mannaioni, G., GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses. PLoS One, 8, 2013, e82180, 10.1371/journal.pone.0082180.
8. Bernstein, C.N., Frankenstein, U.N., Rawsthorne, P., Pitz, M., Summers, R., McIntyre, M.C., Cortical mapping of visceral pain in patients with GI disorders using functional magnetic resonance imaging. Am. J. Gastroenterol. 97 (2002), 319–327, 10.1111/j.1572-0241.2002.05464.x.
9. Bertolino, M., Vicini, S., Costa, E., Kynurenic acid inhibits the activation of kainic and N-methyl-D-aspartic acid-sensitive ionotropic receptors by a different mechanism. Neuropharmacology 28 (1989), 453–457, 10.1016/0028-3908(89)90078-6.
10. Bischoff, E., Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. 16 (2004), S11–S14, 10.1038/sj.ijir.3901208.
11. Bourane, S., Garces, A., Venteo, S., Pattyn, A., Hubert, T., Fichard, A., Puech, S., Boukhaddaoui, H., Baudet, C., Takahashi, S., Valmier, J., Carroll, P., Low-threshold mechanoreceptor subtypes selectively express MafA and are specified by Ret signaling. Neuron 64 (2009), 857–870, 10.1016/j.neuron.2009.12.004.
12. Buhner, S., Schemann, M., Mast cell-nerve axis with a focus on the human gut. Biochim. Biophys. Acta 1822 (2012), 85–92, 10.1016/j.bbadis.2011.06.004.
13. Capuano, A., De Corato, A., Treglia, M., Tringali, G., Dello Russo, C., Navarra, P., Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test: a combination analysis study. Eur. J. Pharmacol. 605 (2009), 57–62, 10.1016/j.ejphar.2008.12.029.
14. Casas, K.A., Mononen, T.K., Mikail, C.N., Hassed, S.J., Li, S., Mulvihill, J.J., Lin, H.J., Falk, R.E., Chromosome 2q terminal deletion: report of 6 new patients and review of phenotype-breakpoint correlations in 66 individuals. Am. J. Med. Genet. A 130A (2004), 331–339, 10.1002/ajmg.a.30156.
15. Carpenedo, R., Pittaluga, A., Cozzi, A., Attucci, S., Galli, A., Raiteri, M., Moroni, F., Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 13 (2001), 2141–2147, 10.1046/j.0953-816x.2001.01592.x.
16. Chassaing, N., De Mas, P., Tauber, M., Vincent, M.C., Julia, S., Bourrouillou, G., Calvas, P., Bieth, E., Molecular characterization of a cryptic 2q37 deletion in a patient with Albright hereditary osteodystrophy-like phenotype. Am. J. Med. Genet. A 128A (2004), 410–413, 10.1002/ajmg.a.30199.
17. Chong, W.W., Lo, I.F., Lam, S.T., Wang, C.C., Luk, H.M., Leung, T.Y., Choy, K.W., Performance of chromosomal microarray for patients with intellectual disabilities/developmental delay, autism, and multiple congenital anomalies in a Chinese cohort. Mol. Cytogenet., 7, 2014, 34, 10.1186/1755-8166-7-34.
18. Cosi, C., Mannaioni, G., Cozzi, A., Carlà, V., Sili, M., Cavone, L., Maratea, D., Moroni, F., G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacology 60 (2011), 1227–1231, 10.1016/j.neuropharm.2010.11.014.
19. Davidson, E.M., Coggeshall, R.E., Carlton, S.M., Peripheral NMDA and non-NMDA glutamate receptors contribute to nociceptive behaviors in the rat formalin test. Neuroreport 8 (1997), 941–946.
20. Deng, H., Fang, Y., Anti-inflammatory gallic acid and wedelolactone are G protein-coupled receptor-35 agonists. Pharmacology 89 (2012), 211–219, 10.1159/000337184.
21. Deng, H., Fang, Y., Aspirin metabolites are GPR35 agonists. Naunyn Schmiedeb. Arch. Pharmacol. 385 (2012), 729–737, 10.1007/s00210-012-0752-0.
22. Deng, H., Hu, H., Fang, Y., Tyrphostin analogs are GPR35 agonists. FEBS Lett. 585 (2011), 1957–1962, 10.1016/j.febslet.2011.05.026.
23. Deng, H., Hu, H., He, M., Hu, J., Niu, W., Ferrie, A.M., Fang, Y., Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists. J. Med. Chem. 54 (2011), 7385–7396, 10.1021/jm200999f.
24. Deng, H., Hu, H., Fang, Y., Multiple tyrosine metabolites are GPR35 agonists. Sci. Rep., 2, 2012, 373, 10.1038/srep00373.
25. Deng, H., Hu, J., Hu, H., He, M., Fang, Y., Thieno[3,2-b]thiophene-2-carboxylic acid derivatives as GPR35 agonists. Bioorg. Med. Chem. Lett. 22 (2012), 4148–4152, 10.1016/j.bmcl.2012.04.057.
26. Devillard, F., Guinchat, V., Moreno-De-Luca, D., Tabet, A.C., Gruchy, N., Guillem, P., Nguyen Morel, M.A., Leporrier, N., Leboyer, M., Jouk, P.S., Lespinasse, J., Betancur, C., Paracentric inversion of chromosome 2 associated with cryptic duplication of 2q14 and deletion of 2q37 in a patient with autism. Am. J. Med. Genet. A 152A (2010), 2346–2354, 10.1002/ajmg.a.33601.
27. De Winter, B.Y., van den Wijngaard, R.M., de Jonge, W.J., Intestinal mast cells in gut inflammation and motility disturbances. Biochim. Biophys. Acta 1822 (2012), 66–73, 10.1016/j.bbadis.2011.03.016.
28. DiNatale, B.C., Murray, I.A., Schroeder, J.C., Flaveny, C.A., Lahoti, T.S., Laurenzana, E.M., Omiecinski, C.J., Perdew, G.H., Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 115 (2010), 89–97, 10.1093/toxsci/kfq024.
29. Divorty, N., Mackenzie, A.E., Nicklin, S.A., Milligan, G., G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Front. Pharmacol., 6, 2015, 41, 10.3389/fphar.2015.00041.
30. Dodd, S., Maes, M., Anderson, G., Dean, O.M., Moylan, S., Berk, M., Putative neuroprotective agents in neuropsychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 42 (2013), 135–145, 10.1016/j.pnpbp.2012.11.007.
31. Ellinghaus, D., Folseraas, T., Holm, K., Ellinghaus, E., Melum, E., Balschun, T., Laerdahl, J.K., Shiryaev, A., Gotthardt, D.N., Weismüller, T.J., Schramm, C., Wittig, M., Bergquist, A., Björnsson, E., Marschall, H.U., Vatn, M., Teufel, A., Rust, C., Gieger, C., Wichmann, H.E., Runz, H., Sterneck, M., Rupp, C., Braun, F., Weersma, R.K., Wijmenga, C., Ponsioen, C.Y., Mathew, C.G., Rutgeerts, P., Vermeire, S., Schrumpf, E., Hov, J.R., Manns, M.P., Boberg, K.M., Schreiber, S., Franke, A., Karlsen, T.H., Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 58 (2013), 1074–1083, 10.1002/hep.25977.
32. Falk, R.E., Casas, K.A., Chromosome 2q37 deletion: clinical and molecular aspects. Am. J. Med. Genet. C 145C (2007), 357–371, 10.1002/ajmg.c.30153.
33. Fallarini, S., Magliulo, L., Paoletti, T., de Lalla, C., Lombardi, G., Expression of functional GPR35 in human iNKT cells. Biochem. Biophys. Res. Commun. 398 (2010), 420–425, 10.1111/j.1476-5381.2012.02108.x.
34. Fawcett, L., Baxendale, R., Stacey, P., McGrouther, C., Harrow, I., Soderling, S., Hetman, J., Beavo, J.A., Phillips, S.C., Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 3702–3707, 10.1073/pnas.97.7.3702.
35. Fernández-Rebollo, E., Pérez, O., Martinez-Bouzas, C., Cotarelo-Pérez, M.C., Garin, I., Ruibal, J.L., Pérez-Nanclares, G., Castaño, L., de Nanclares, G.P., Two cases of deletion 2q37 associated with segregation of an unbalanced translocation 2;21: choanal atresia leading to misdiagnosis of CHARGE syndrome. Eur. J. Endocrinol. 160 (2009), 711–777, 10.1530/EJE-08-0865.
36. Fisher, D.A., Smith, J.F., Pillar, J.S., St Denis, S.H., Cheng, J.B., Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273 (1998), 15559–15564, 10.1074/jbc.273.25.15559.
37. Franck, M.C., Stenqvist, A., Li, L., Hao, J., Usoskin, D., Xu, X., Wiesenfeld-Hallin, Z., Ernfors, P., Essential role of Ret for defining non-peptidergic nociceptor phenotypes and functions in the adult mouse. Eur. J. Neurosci. 33 (2011), 1385–1400, 10.1111/j.1460-9568.2011.07634.x.
38. Fujishige, K., Kotera, J., Michibata, H., Yuasa, K., Takebayashi, S., Okumura, K., Omori, K., Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. 274 (1999), 18438–18445, 10.1074/jbc.274.26.18438.
39. Funke, M., Thimm, D., Schiedel, A.C., Müller, C.E., 8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35. J. Med. Chem. 56 (2013), 5182–5197, 10.1021/jm400587g.
40. Ghaziuddin, M., Burmeister, M., Deletion of chromosome 2q37 and autism: a distinct subtype?. J. Autism Dev. Disord. 29 (1999), 259–263, 10.1023/A:1023088207468.
41. Guo, J., Williams, D.J., Puhl, H.L. 3rd, Ikeda, S.R., Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons. J. Pharmacol. Exp. Ther. 324 (2008), 342–351, 10.1124/jpet.107.127266.
42. Heo, B.Y., Kim, C.M., Jeong, S.T., Kim, S.J., Choi, J., Yoon, M.H., Antinociceptive effect of the intrathecal phosphodiesterase inhibitor, zaprinast, in a rat formalin test. Korean J. Pain 18 (2005), 99–106, 10.3344/kjp.2005.18.2.99.
43. Heynen-Genel, S., Dahl, R., Shi, S., Sauer, M., Hariharan, S., Sergienko, E., Dad, S., Chung, T.D.Y., Stonich, D., Su, Y., Caron, M.G., Zhao, P., Abood, M.E., Barak, L.S., Antagonists for the Orphan Receptor GPR35., 2010, Sanford-Burnham Centre for Chemical Genomics Probe Report 1 & 2.
44. Heynen-Genel, S., Dahl, R., Shi, S., Sauer, M., Hariharan, S., Sergienko, E., Dad, S., Chung, T.D.Y., Stonich, D., Su, Y., Zhao, P., Caron, M.G., Abood, M.E., Barak, L.S., Antagonists for the Orphan Receptor GPR35., 2011, Sanford-Burnham Centre for Chemical Genomics Probe Report 3.
45. Hilger, A., Schramm, C., Pennimpede, T., Wittler, L., Dworschak, G.C., Bartels, E., Engels, H., Zink, A.M., Degenhardt, F., Müller, A.M., Schmiedeke, E., Grasshoff-Derr, S., Märzheuser, S., Hosie, S., Holland-Cunz, S., Wijers, C.H., Marcelis, C.L., van Rooij, I.A., Hildebrandt, F., Herrmann, B.G., Nöthen, M.M., Ludwig, M., Reutter, H., Draaken, M., De novo microduplications at 1q41, 2q37.3, and 8q24.3 in patients with VATER/VACTERL association. Eur. J. Hum. Genet. 21 (2013), 1377–1382, 10.1038/ejhg.2013.58.
46. Hilmas, C., Pereira, E.F., Alkondon, M., Rassoulpour, A., Schwarcz, R., Albuquerque, E.X., The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21 (2001), 7463–7473.
47. Horikawa, Y., Oda, N., Cox, N.J., Li, X., Orho-Melander, M., Hara, M., Hinokio, Y., Lindner, T.H., Mashima, H., Schwarz, P.E., del Bosque-Plata, L., Horikawa, Y., Oda, Y., Yoshiuchi, I., Colilla, S., Polonsky, K.S., Wei, S., Concannon, P., Iwasaki, N., Schulze, J., Baier, L.J., Bogardus, C., Groop, L., Boerwinkle, E., Hanis, C.L., Bell, G.I., Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat. Genet. 26 (2000), 163–175, 10.1038/79876.
48. Imielinski, M., Baldassano, R.N., Griffiths, A., Russell, R.K., Annese, V., Dubinsky, M., Kugathasan, S., Bradfield, J.P., Walters, T.D., Sleiman, P., Kim, C.E., Muise, A., Wang, K., Glessner, J.T., Saeed, S., Zhang, H., Frackelton, E.C., Hou, C., Flory, J.H., Otieno, G., Chiavacci, R.M., Grundmeier, R., Castro, M., Latiano, A., Dallapiccola, B., Stempak, J., Abrams, D.J., Taylor, K., McGovern, D., Western Regional Alliance for Pediatric IBD, Silber, G., Wrobel, I., Quiros, A. International IBD Genetics Consortium, Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux, J.D., Brant, S.R., Silverberg, M.S., Taylor, K.D., Barmuda, M.M., Bitton, A., Dassopoulos, T., Datta, L.W., Green, T., Griffiths, A.M., Kistner, E.O., Murtha, M.T., Regueiro, M.D., Rotter, J.I., Schumm, L.P., Steinhart, A.H., Targan, S.R., Xavier, R.J. NIDDK IBD Genetics Consortium, Libioulle, C., Sandor, C., Lathrop, M., Belaiche, J., Dewit, O., Gut, I., Heath, S., Laukens, D., Mni, M., Rutgeerts, P., Van Gossum, A., Zelenika, D., Franchimont, D., Hugot, J.P., de Vos, M., Vermeire, S., Louis, E. Belgian-French IBD Consortium Wellcome Trust Case Control Consortium, Cardon, L.R., Anderson, C.A., Drummond, H., Nimmo, E., Ahmad, T., Prescott, N.J., Onnie, C.M., Fisher, S.A., Marchini, J., Ghori, J., Bumpstead, S., Gwillam, R., Tremelling, M., Delukas, P., Mansfield, J., Jewell, D., Satsangi, J., Mathew, C.G., Parkes, M., Georges, M., Daly, M.J., Heyman, M.B., Ferry, G.D., Kirschner, B., Lee, J., Essers, J., Grand, R., Stephens, M., Levine, A., Piccoli, D., Van Limbergen, J., Cucchiara, S., Monos, D.S., Guthery, S.L., Denson, L., Wilson, D.C., Grant, S.F., Daly, M., Silverberg, M.S., Satsangi, J., Hakonarson, H., Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat. Genet. 41 (2009), 1335–1340, 10.1038/ng.489.
49. Im, D.S., Intercellular lipid mediators and GPCR drug discovery. Biomol. Ther. (Seoul) 21 (2013), 411–422, 10.4062/biomolther.2013.080.
50. Ishii, M., Iwai, M., Harada, Y., Morikawa, T., Okanoue, T., Kishikawa, T., Tsuchihashi, Y., Hanai, K., Arizono, N., A role of mast cells for hepatic fibrosis in primary sclerosing cholangitis. Hepatol. Res. 31 (2005), 127–131, 10.1016/j.hepres.2005.01.007.
51. Jenkins, L., Brea, J., Smith, N.J., Hudson, B.D., Reilly, G., Bryant, N.J., Castro, M., Loza, M.I., Milligan, G., Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13. Biochem. J. 432 (2010), 451–459, 10.1042/BJ20101287.
52. Jenkins, L., Alvarez-Curto, E., Campbell, K., de Munnik, S., Canals, M., Schlyer, S., Milligan, G., Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα13 and β-arrestin-2. Br. J. Pharmacol. 162 (2011), 733–748, 10.1111/j.1476-5381.2010.01082.x.
53. Jenkins, L., Harries, N., Lappin, J.E., MacKenzie, A.E., Neetoo-Isseljee, Z., Southern, C., McIver, E.G., Nicklin, S.A., Taylor, D.L., Milligan, G., Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J. Pharmacol. Exp. Ther. 343 (2012), 683–695, 10.1124/jpet.112.198945.
54. Jensen, K., Hoo, J.J., Is brachydactyly type Ballard a variant of brachydactyly type E?. Am. J. Med. Genet. A 129A (2004), 95–97, 10.1002/ajmg.a.30159.
55. Kennedy, L.L., Hargrove, L.A., Graf, A.B., Francis, T.C., Hodges, K.M., Nguyen, Q.P., Ueno, Y., Greene, J.F., Meng, F., Huynh, V.D., Francis, H.L., Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents. Lab. Investig. 94 (2014), 1406–1418, 10.1038/labinvest.2014.129.
56. Kessler, M., Terramani, T., Lynch, G., Baudry, M., A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J. Neurochem. 52 (1989), 1319–1328, 10.1111/j.1471-4159.1989.tb01881.x.
57. Kruse, L.S., Møller, M., Tibaek, M., Gammeltoft, S., Olesen, J., Kruuse, C., PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system. Brain Res. 1281 (2009), 25–34, 10.1016/j.brainres.2009.05.012.
58. Lakhan, S.E., Kirchgessner, A., Neuroinflammation in inflammatory bowel disease. J. Neuroinflammation, 7, 2010, 37, 10.1186/1742-2094-7-37.
59. Lee, J., Saloman, J.L., Weiland, G., Auh, Q.S., Chung, M.K., Ro, J.Y., Functional interactions between NMDA receptors and TRPV1 in trigeminal sensory neurons mediate mechanical hyperalgesia in the rat masseter muscle. Pain 153 (2012), 1514–1524, 10.1016/j.pain.2012.04.015.
60. Leonard, J. N., Chu, Z. L., Unett, D. J., Gatlin, J. E., Gaidarov, I., Qiu, J., Skinner, P. J., Boatman, D., Hume, S. A., Kellie, M. J., and Sweet Oatman, P. D. (2007). GPR35 and Modulators Thereof for the Treatment of Metabolic-related Disorders. United States 20070077602.
61. Loughney, K., Hill, T.R., Florio, V.A., Uher, L., Rosman, G.J., Wolda, S.L., Jones, B.A., Howard, M.L., McAllister-Lucas, L.M., Sonnenburg, W.K., Francis, S.H., Corbin, J.D., Beavo, J.A., Ferguson, K., Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene 216 (1998), 139–147, 10.1016/S0378-1119(98)00303-5.
62. Lugnier, C., Schoeffter, P., Le Bec, A., Strouthou, E., Stoclet, J.C., Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35 (1986), 1743–1751, 10.1016/0006-2952(86)90333-3.
63. Luo, W., Enomoto, H., Rice, F.L., Milbrandt, J., Ginty, D.D., Molecular identification of rapidly adapting mechanoreceptors and their developmental dependence on ret signaling. Neuron 64 (2009), 841–856, 10.1016/j.neuron.2009.11.003.
64. Mackenzie, A.E., Lappin, J.E., Taylor, D.L., Nicklin, S.A., Milligan, G., GPR35 as a novel therapeutic target. Front. Endocrinol. (Lausanne), 2, 2011, 68, 10.3389/fendo.2011.00068.
65. Mackenzie, A.E., Caltabiano, G., Kent, T.C., Jenkins, L., McCallum, J.E., Hudson, B.D., Nicklin, S.A., Fawcett, L., Markwick, R., Charlton, S.J., Milligan, G., The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol. Pharmacol. 85 (2014), 91–104, 10.1124/mol.113.089482.
66. Malmberg, A.B., Yaksh, T.L., Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J. Pharmacol. Exp. Ther. 263 (1992), 136–146.
67. Malmberg, A.B., Yaksh, T.L., Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction. Anesthesiology 79 (1993), 270–281.
68. Maravillas-Montero, J.L., Burkhardt, A.M., Hevezi, P.A., Carnevale, C.D., Smit, M.J., Zlotnik, A., Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17. J. Immunol. 194 (2014), 29–33, 10.4049/jimmunol.1401704.
69. Martindale, J., Bland-Ward, P.A., Chessell, I.P., Inhibition of C-fibre mediated sensory transmission in the rat following intraplantar formalin. Neurosci. Lett. 316 (2001), 33–36, 10.1016/S0304-3940(01)02362-X.
70. McCall, W.D., Tanner, K.D., Levine, J.D., Formalin induces biphasic activity in C-fibers in the rat. Neurosci. Lett. 208 (1996), 45–48.
71. Michel, M.C., Wieland, T., Tsujimoto, G., How reliable are G-protein-coupled receptor antibodies?. Naunyn Schmiedeb. Arch. Pharmacol. 379 (2009), 385–388, 10.1007/s00210-009-0395-y.
72. Milligan, G., Orthologue selectivity and ligand bias: translating the pharmacology of GPR35. Trends Pharmacol. Sci. 32 (2011), 317–325, 10.1016/j.tips.2011.02.002.
73. Min, K.D., Asakura, M., Liao, Y., Nakamaru, K., Okazaki, H., Takahashi, T., Fujimoto, K., Ito, S., Takahashi, A., Asanuma, H., Yamazaki, S., Minamino, T., Sanada, S., Seguchi, O., Nakano, A., Ando, Y., Otsuka, T., Furukawa, H., Isomura, T., Takashima, S., Mochizuki, N., Kitakaze, M., Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem. Biophys. Res. Commun. 393 (2010), 55–60, 10.1016/j.bbrc.2010.01.076.
74. Mixcoatl-Zecuatl, T., Aguirre-Bañuelos, P., Granados-Soto, V., Sildenafil produces antinociception and increases morphine antinociception in the formalin test. Eur. J. Pharmacol. 400 (2000), 81–87, 10.1016/S0014-2999(00)00361-7.
75. Mok, M.H., Fricker, A.C., Weil, A., Kew, J.N., Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology 57 (2009), 242–249, 10.1016/j.neuropharm.2009.06.003.
76. Moroni, F., Cozzi, A., Sili, M., Mannaioni, G., Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J. Neural Transm. 119 (2012), 133–139, 10.1007/s00702-011-0763-x.
77. Nakamizo, T., Kawamata, J., Yoshida, K., Kawai, Y., Kanki, R., Sawada, H., Kihara, T., Yamashita, H., Shibasaki, H., Akaike, A., Shimohama, S., Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J. Neurosci. Res. 71 (2003), 485–495, 10.1002/jnr.10483.
78. Neetoo-Isseljee, Z., MacKenzie, A.E., Southern, C., Jerman, J., McIver, E.G., Harries, N., Taylor, D.L., Milligan, G., High-throughput identification and characterization of novel, species-selective GPR35 agonists. J. Pharmacol. Exp. Ther. 344 (2013), 568–578, 10.1124/jpet.112.201798.
79. O'Dowd, B.F., Nguyen, T., Marchese, A., Cheng, R., Lynch, K.R., Heng, H.H., Kolakowski, L.F. Jr., George, S.R., Discovery of three novel G-protein-coupled receptor genes. Genomics 47 (1998), 310–313, 10.1006/geno.1998.5095.
80. Ohshiro, H., Tonai-Kachi, H., Ichikawa, K., GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem. Biophys. Res. Commun. 365 (2008), 344–348, 10.1016/j.bbrc.2007.10.197.
81. Oka, S., Ota, R., Shima, M., Yamashita, A., Sugiura, T., GPR35 is a novel lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 395 (2010), 232–237, 10.1016/j.bbrc.2010.03.169.
82. Okumura, S., Baba, H., Kumada, T., Nanmoku, K., Nakajima, H., Nakane, Y., Hioki, K., Ikenaka, K., Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells. Cancer Sci. 95 (2004), 131–135, 10.1111/j.1349-7006.2004.tb03193.x.
83. Oluyomi, A.O., Hart, S.L., Smith, T.W., Differential antinociceptive effects of morphine and methylmorphine in the formalin test. Pain 49 (1992), 415–418, 10.1016/0304-3959(92)90249-B.
84. Patel, D.R., Young, A.M.J., Croucher, M.J., Presynaptic α-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor-mediated stimulation of glutamate and GABA release in the rat striatum in vivo: a dual-label microdialysis study. Neuroscience 102 (2001), 101–111, 10.1016/S0306-4522(00)00463-2.
85. Paul-Clark, M.J., Van Cao, T., Moradi-Bidhendi, N., Cooper, D., Gilroy, D.W., 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med. 200 (2004), 69–78, 10.1084/jem.20040566.
86. Prescott, C., Weeks, A.M., Staley, K.J., Partin, K.M., Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett. 402 (2006), 108–112, 10.1016/j.neulet.2006.03.051.
87. Rijnierse, A., Nijkamp, F.P., Kraneveld, A.D., Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol. Ther. 116 (2007), 207–235, 10.1016/j.pharmthera.2007.06.008.
88. Ringel, M.D., Schwindinger, W.F., Levine, M.A., Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 75 (1996), 171–184, 10.1097/00005792-199607000-00001.
89. Ronkainen, V.P., Tuomainen, T., Huusko, J., Laidinen, S., Malinen, M., Palvimo, J.J., Ylä-Herttuala, S., Vuolteenaho, O., Tavi, P., Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling. Cardiovasc. Res. 101 (2014), 69–77, 10.1093/cvr/cvt226.
90. Sapunar, D., Kostic, S., Banozic, A., Puljak, L., Dorsal root ganglion - a potential new therapeutic target for neuropathic pain. J. Pain Res. 5 (2012), 31–38, 10.2147/JPR.S26603.
91. Sasaki, Y., Tanaka, M., Kudo, H., Differentiation between ulcerative colitis and Crohn's disease by a quantitative immunohistochemical evaluation of T lymphocytes, neutrophils, histiocytes and mast cells. Pathol. Int. 52 (2002), 277–285, 10.1046/j.1440-1827.2002.01354.x.
92. Sevostianova, N., Danysz, W., Bespalov, A.Y., Analgesic effects of morphine and loperamide in the rat formalin test: interactions with NMDA receptor antagonists. Eur. J. Pharmacol. 525 (2005), 83–90, 10.1016/j.ejphar.2005.10.010.
93. Shelukhina, I., Paddenberg, R., Kummer, W., Tsetlin, V., Functional expression and axonal transport of α7 nAChRs by peptidergic nociceptors of rat dorsal root ganglion. Brain Struct. Funct., 2014, 10.1007/s00429-014-0762-4 [Epub ahead of print].
94. Shore, D.M., Reggio, P.H., The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front. Pharmacol., 6, 2015, 69, 10.3389/fphar.2015.00069.
95. Shrimpton, A.E., Braddock, B.R., Thomson, L.L., Stein, C.K., Hoo, J.J., Molecular delineation of deletions on 2q37.3 in three cases with an Albright hereditary osteodystrophy-like phenotype. Clin. Genet. 66 (2004), 537–544, 10.1111/j.1399-0004.2004.00363.x.
96. Siebel, S., Solomon, B.D., Mitochondrial factors and VACTERL association-related congenital malformations. Mol. Syndromol. 4 (2013), 63–73, 10.1159/000346301.
97. Smith, M., Escamilla, J.R., Filipek, P., Bocian, M.E., Modahl, C., Flodman, P., Spence, M.A., Molecular genetic delineation of 2q37.3 deletion in autism and osteodystrophy: report of a case and of new markers for deletion screening by PCR. Cytogenet. Cell Genet. 94 (2001), 15–22, 10.1159/000048775.
98. Solomon, B.D., VACTERL/VATER association. Orphanet. J. Rare Dis., 6, 2011, 56, 10.1186/1750-1172-6-56.
99. Southern, C., Cook, J.M., Neetoo-Isseljee, Z., Taylor, D.L., Kettleborough, C.A., Merritt, A., Bassoni, D.L., Raab, W.J., Quinn, E., Wehrman, T.S., Davenport, A.P., Brown, A.J., Green, A., Wigglesworth, M.J., Rees, S., Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J. Biomol. Screen. 18 (2013), 599–609, 10.1177/1087057113475480.
100. Stead, R.H., Colley, E.C., Wang, B., Partosoedarso, E., Lin, J., Stanisz, A., Hillsley, K., Vagal influences over mast cells. Auton. Neurosci. 125 (2006), 53–61, 10.1016/j.autneu.2006.01.002.
101. Strack, I., Schulte, S., Varnholt, H., Schievenbusch, S., Töx, U., Wendland, K., Steffen, H.M., Drebber, U., Dienes, H.P., Odenthal, M., β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Lab. Investig. 91 (2011), 252–261, 10.1038/labinvest.2010.162.
102. Sun, Y.V., Bielak, L.F., Peyser, P.A., Turner, S.T., Sheedy, P.F. 2nd, Boerwinkle, E., Kardia, S.L., Application of machine learning algorithms to predict coronary artery calcification with a sibship-based design. Genet. Epidemiol. 32 (2008), 350–360, 10.1002/gepi.20309.
103. Taher, A., Schulz-Knappe, P., Meyer, M., Truss, M., Forssmann, W.G., Stief, C.G., Jonas, U., Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro. World J. Urol. 12 (1994), 286–291, 10.1007/BF00191209.
104. Taniguchi, Y., Tonai-Kachi, H., Shinjo, K., Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 580 (2006), 5003–5008, 10.1016/j.febslet.2006.08.015.
105. Taniguchi, Y., Tonai-Kachi, H., Shinjo, K., 5-Nitro-2-(3-phenylpropylamino)benzoic acid is a GPR35 agonist. Pharmacology 82 (2008), 245–249, 10.1159/000157625.
106. Thimm, D., Funke, M., Meyer, A., Müller, C.E., 6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid: a powerful tool for studying orphan G protein-coupled receptor GPR35. J. Med. Chem. 56 (2013), 7084–7099, 10.1021/jm4009373.
107. Vaccarino, A.L., Marek, P., Kest, B., Weber, E., Keana, J.F., Liebeskind, J.C., NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res. 615 (1993), 331–334, 10.1016/0006-8993(93)90045-O.
108. van Karnebeek, C.D., Koevoets, C., Sluijter, S., Bijlsma, E.K., Smeets, D.F., Redeker, E.J., Hennekam, R.C., Hoovers, J.M., Prospective screening for subtelomeric rearrangements in children with mental retardation of unknown aetiology: the Amsterdam experience. J. Med. Genet. 39 (2002), 546–553, 10.1136/jmg.39.8.546.
109. Vermeulen, W., De Man, J.G., Pelckmans, P.A., De Winter, B.Y., Neuroanatomy of lower gastrointestinal pain disorders. World J. Gastroenterol. 20 (2014), 1005–1120, 10.3748/wjg.v20.i4.1005.
110. Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., Ling, L., Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281 (2006), 22021–22028, 10.1074/jbc.M603503200.
111. Wheeler, D.B., Randall, A., Tsien, R.W., Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission. Science 264 (1994), 107–111, 10.1126/science.7832825.
112. Xu, X., Weksler-Zangen, S., Pikarsky, A., Pappo, O., Wengrower, D., Bischoff, S.C., Pines, M., Rivkind, A., Goldin, E., Levi-Schaffer, F., Mast cells involvement in the inflammation and fibrosis development of the TNBS-induced rat model of colitis. Scand. J. Gastroenterol. 37 (2002), 330–337, 10.1080/003655202317284246.
113. Yang, S.K., Hong, M., Choi, H., Zhao, W., Jung, Y., Haritunians, T., Ye, B.D., Kim, K.J., Park, S.H., Lee, I., Kim, W.H., Cheon, J.H., Kim, Y.H., Jang, B.I., Kim, H.S., Choi, J.H., Koo, J.S., Lee, J.H., Jung, S.A., Shin, H.D., Kang, D., Youn, H.S., Taylor, K.D., Rotter, J.I., Liu, J., McGovern, D.P., Song, K., Immunochip analysis identification of 6 additional susceptibility loci for Crohn's disease in Koreans. Inflamm. Bowel Dis. 21 (2015), 1–7, 10.1097/MIB.0000000000000268.
114. Yang, Y., Lu, J.Y., Wu, X., Summer, S., Whoriskey, J., Saris, C., Reagan, J.D., G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 86 (2010), 1–5, 10.1159/000314164.
115. Yang, Y., Fu, A., Wu, X., Reagan, J.D., GPR35 is a target of the loop diuretic drugs bumetanide and furosemide. Pharmacology 89 (2012), 13–17, 10.1159/000335127.
116. Yoon, M.H., Choi, J.I., Bae, H.B., Jeong, S.W., Chung, S.S., Yoo, K.Y., Jeong, C.Y., Kim, S.J., Chung, S.T., Kim, C.M., Lack of the nitric oxide-cyclic GMP-potassium channel pathway for the antinociceptive effect of intrathecal zaprinast in a rat formalin test. Neurosci. Lett. 390 (2005), 114–117, 10.1016/j.neulet.2005.08.006.
117. Yuasa, K., Kotera, J., Fujishige, K., Michibata, H., Sasaki, T., Omori, K., Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J. Biol. Chem. 275 (2000), 31469–31479, 10.1074/jbc.M003041200.
118. Zhao, P., Sharir, H., Kapur, A., Cowan, A., Geller, E.B., Adler, M.W., Seltzman, H.H., Reggio, P.H., Heynen-Genel, S., Sauer, M., Chung, T.D., Bai, Y., Chen, W., Caron, M.G., Barak, L.S., Abood, M.E., Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol. Pharmacol. 78 (2010), 560–568, 10.1124/mol.110.066746.
119. Zhao, P., Abood, M.E., GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci. 92 (2013), 453–457, 10.1016/j.lfs.2012.06.039.